1. What Is the COPD Market?
The COPD Market covers the medicines used to manage the chronic obstructive pulmonary disease that affects over 300 million people globally with the progressive airflow limitation, the exacerbations, and the mortality. The cigarette smoke and the occupational exposure create the airway inflammation and the emphysematous destruction of the lung parenchyma. The FEV1 decline below 70 percent of predicted identifies the GOLD diagnostic criterion. COPD pharmacological management uses the short-acting and long-acting bronchodilators of the beta2-agonist and the muscarinic antagonist classes that improve the airflow obstruction, reduce the hyperinflation, and relieve the dyspnoea. The inhaled corticosteroid is added for the eosinophilic COPD phenotype with the blood eosinophil above 300 cells per microlitre or the frequent exacerbation history. The COPD market is transformed by the dupilumab BOREAS and NOTUS Phase III trials demonstrating 30 percent exacerbation reduction in the eosinophilic COPD patients above 300 cells per microlitre on triple inhaled therapy. The trials establish the first biologic indication in COPD.
2. COPD Market Size & Forecast
3. Emerging Technologies
- Triple therapy ICS-LABA-LAMA Trelegy Ellipta and Breztri Aerosphere head-to-head IMPACT and ETHOS trials demonstrated the triple combination superiority over the dual bronchodilator and the dual ICS-LABA. The superiority covered the exacerbation prevention and the FEV1 improvement in the moderate to severe COPD patients. The patients had frequent exacerbation or significant airflow limitation. The single-inhaler triple therapy is now the standard for the high-risk COPD patient.
- Dupilumab BOREAS and NOTUS COPD Phase III demonstrated 30 percent exacerbation reduction and 160 mL FEV1 improvement in the eosinophilic COPD above 300 cells per microlitre on top of optimised triple therapy. The first add-on biologic for COPD addresses the Type 2 eosinophilic inflammation. The inhaled corticosteroid incompletely suppresses the Type 2 inflammation.
- Roflumilast PDE4 inhibitor for the severe COPD with the chronic bronchitis phenotype and the exacerbation history demonstrated the 17 percent exacerbation reduction versus placebo in the ATEM and M2-124 and M2-125 trials. The add-on oral anti-inflammatory serves the severe chronic bronchitis patient. The patient continues to exacerbate on the bronchodilator and the ICS therapy.
- Azithromycin long-term macrolide antibiotic prophylaxis for the COPD patient with three or more exacerbations per year demonstrated the 27 percent exacerbation reduction in the ALBERT trial. The anti-inflammatory and the anti-infective mechanism provides the reduction. The off-label chronic macrolide strategy serves the carefully selected COPD patient.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Asthma Market.
4. Key Market Opportunity
Within the COPD market, a leading opportunity is dupilumab COPD market expansion with type 2 inflammation patient identification, where the biologic precision therapy approval drives prescribing in the substantial type 2 inflammation COPD subset. Sanofi and Regeneron capturing growing dupilumab COPD prescribing reflect this biologic precision opportunity. A parallel growth driver is driven by ensifentrine novel mechanism adoption. As dupilumab COPD adoption proceeds and ensifentrine prescribing grows, the addressable opportunity is expanding from inhaler-only COPD treatment toward biologic and novel mechanism precision therapy.
5. Top Companies in the COPD Market
The following organisations hold leading positions in the COPD Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- GSK
- AstraZeneca
- Boehringer Ingelheim
- Novartis
- Sanofi
- Regeneron
- Verona Pharma
- Merck
- Roche
- Chiesi Farmaceutici
- Cipla
- Sun Pharma
- Lupin
- Viatris
- Glenmark Pharmaceuticals
- Theravance Biopharma
6. Market Segmentation
The COPD Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | LAMALABAICSLAMA-LABA-ICS TripleBiologic |
| By Severity | GOLD ABCD |
| By Phenotype | EosinophilicFrequent ExacerbatorMucus Hypersecreting |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the COPD Market trajectory over the forecast period:
Dupilumab BOREAS and NOTUS COPD 30 Percent Exacerbation Reduction Plus 160 mL FEV1 Improvement in Eosinophilic Phenotype Above 300 Cells on Triple Therapy Represents the First Biologic Indication in COPD That Addresses the Type 2 Inflammation That Inhaled Corticosteroids Incompletely Suppress.Verona Pharma's ensifentrine demonstrated 145 mL improvement in trough FEV1 as add-on to LAMA, LABA-ICS, or triple therapy in ENHANCE-1 and ENHANCE-2 trials, with 41% exacerbation reduction in GOLD B-E patients on background bronchodilators. The dual PDE3 inhibition driving bronchodilation and PDE4 inhibition driving anti-inflammatory effects in a single inhaled agent provides mechanism complementarity that neither LAMA nor LABA achieves, and the absence of systemic PDE4 inhibitor side effects of oral roflumilast including nausea and diarrhoea makes ensifentrine appropriate for outpatient add-on therapy. Ensifentrine represents the first novel COPD mechanism approved since the ICS-LABA-LAMA triple inhaler became the guideline-recommended intensification step, establishing that the COPD drug class retains innovation space beyond the incumbent bronchodilator classes.
Single-Inhaler Triple Therapy ICS-LABA-LAMA IMPACT and ETHOS Superiority Over Dual Therapy for Exacerbation Prevention in High-Risk COPD Has Established the Three-Component Combination as the Standard for the Frequent Exacerbation or Significant Airflow Limitation Patient.Sanofi and Regeneron's BOREAS data showing 30% exacerbation reduction in eosinophil-high COPD positioned dupilumab for FDA approval in a disease where inhaled triple therapy has remained the ceiling of pharmacologic care for over a decade. The eosinophil-high COPD subgroup defined by blood eosinophil count above 300 cells/μL shows consistent treatment response to anti-eosinophilic biologics, establishing a precision medicine framework for biologic prescribing in COPD that parallels the biomarker-stratified approach that has guided severe asthma biologic therapy since mepolizumab's 2015 approval. GOLD 2024 guideline updates incorporating dupilumab as an add-on option for eosinophil-high COPD exacerbators formalise the new treatment algorithm for a biologic-eligible COPD subpopulation of approximately 20 million patients globally.
Azithromycin Long-Term Macrolide Prophylaxis ALBERT Trial 27 Percent Exacerbation Reduction Through Anti-Inflammatory and Anti-Infective Mechanism Has Provided the Off-Label Chronic Macrolide Strategy for the Carefully Selected High-Exacerbation-Frequency COPD Patient.Pulmonx's Zephyr endobronchial valve demonstrated 3.5-point improvement in St. George's Respiratory Questionnaire score and 150 mL FEV1 improvement versus sham bronchoscopy in LIBERATE, establishing a non-surgical lung volume reduction option for severe emphysema patients with significant air trapping and intact interlobar fissures. The valve mechanism creates lobar volume reduction by blocking inhaled airflow while allowing mucus clearance, producing lobar atelectasis that redistributes gas distribution to less emphysematous regions and improves respiratory mechanics. Patient selection using Chartis collateral ventilation assessment and CT fissure analysis identifies the approximately 30% of severe emphysema patients with intact interlobar seals where significant lobar volume reduction is achievable, creating a precision procedural approach within the broad severe COPD population.
For related market intelligence, see the Respiratory Drug Market.
8. Segmental Analysis
By drug class, the long-acting bronchodilator combination segment dominated the COPD Market in 2025, as GSK's Trelegy and Boehringer Ingelheim's dual bronchodilators anchored maintenance treatment across the large symptomatic population, generating the broadest prescription base in the indication.
By phenotype, the eosinophilic segment is projected to register the highest growth rate through 2034, as Sanofi and Regeneron's Dupixent and Verona Pharma's ensifentrine establish biologic and novel inhaled options for patients with frequent exacerbations who were previously limited to bronchodilator therapy.
9. Regional Analysis
Regional demand patterns across the COPD Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the COPD Market in 2025, accounting for approximately 47% of global revenue, due to US premium pricing for triple inhaler combinations, dupilumab COPD, and ensifentrine and the large COPD patient population. Moreover, dupilumab COPD launch and ensifentrine commercial uptake are most advanced in the US. In addition, ICS-LAMA-LABA triple inhaler prescribing is well-established. Regional dominance is attributed to this combination of pricing environment and novel COPD therapy launches.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the COPD Market through 2034, driven by the very large COPD patient population in China and India and expanding access to triple inhaler combinations and emerging COPD biologic and novel mechanism therapy. The region is also witnessing dupilumab COPD adoption growing. Moreover, the demographic and environmental drivers sustain COPD prevalence growth. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The COPD Market was valued at USD 17.96 Bn in 2025 and is projected to reach USD 29.07 Bn by 2034, growing at a CAGR of 5.5% over the 2026–2034 forecast period.
The COPD Market is projected to grow at a CAGR of 5.5% from 2026 to 2034.
North America dominated the COPD Market in 2025, accounting for approximately 47% of global revenue, due to US premium pricing for triple inhaler combinations, dupilumab COPD, and ensifentrine and the large COPD patient population.
The leading companies in the COPD Market include GSK, AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi, Regeneron, Verona Pharma, Merck, Roche, Chiesi Farmaceutici, Cipla, Sun Pharma, Lupin, Viatris, Glenmark Pharmaceuticals, Theravance Biopharma.
Dupilumab boreas and notus copd 30 percent exacerbation reduction plus 160 ml fev1 improvement in eosinophilic phenotype above 300 cells on triple therapy represents the first biologic indication in copd that addresses the type 2 inflammation that inhaled corticosteroids incompletely suppress.
By drug class, the long-acting bronchodilator combination segment dominated the COPD Market in 2025, as GSK's Trelegy and Boehringer Ingelheim's dual bronchodilators anchored maintenance treatment across the large symptomatic population, generating the broadest prescription base in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.